Claire Harrison

34.7k total citations · 6 hit papers
452 papers, 15.0k citations indexed

About

Claire Harrison is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Claire Harrison has authored 452 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 420 papers in Genetics, 307 papers in Hematology and 156 papers in Molecular Biology. Recurrent topics in Claire Harrison's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (409 papers), Chronic Myeloid Leukemia Treatments (188 papers) and Kruppel-like factors research (144 papers). Claire Harrison is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (409 papers), Chronic Myeloid Leukemia Treatments (188 papers) and Kruppel-like factors research (144 papers). Claire Harrison collaborates with scholars based in United Kingdom, United States and Italy. Claire Harrison's co-authors include Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Anthony R. Green, Ruben A. Mesa, Francisco Cervantes, Tiziano Barbui, Mary Frances McMullin, Francesco Passamonti, Srđan Verstovšek and Peter J. Campbell and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Claire Harrison

427 papers receiving 14.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

2012 1.2k citations Claire Harrison, Jean‐Jacques Kiladjian et al. profile →
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis

2007 898 citations Linda M. Scott, Wendy N. Erber et al. profile →
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia

2005 610 citations Claire Harrison et al. profile →
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

2015 594 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. profile →
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

2016 350 citations Claire Harrison, Alessandro M. Vannucchi et al. Leukemia profile →
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

2015 340 citations Claire Harrison, Francisco Cervantes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claire Harrison United Kingdom	58	12.8k	9.4k	7.7k	5.1k	1.2k	452	15.0k
Francesco Passamonti Italy	59	14.9k 1.2×	11.3k 1.2×	8.6k 1.1×	5.8k 1.1×	1.6k 1.3×	316	17.3k
Jean‐Jacques Kiladjian France	49	9.4k 0.7×	7.4k 0.8×	5.4k 0.7×	4.0k 0.8×	1.0k 0.9×	381	12.0k
Alessandro M. Vannucchi Italy	78	19.2k 1.5×	14.8k 1.6×	12.1k 1.6×	7.7k 1.5×	1.6k 1.4×	549	23.0k
Francisco Cervantes Spain	64	15.8k 1.2×	14.5k 1.5×	7.6k 1.0×	7.1k 1.4×	1.5k 1.3×	321	20.0k
Martha Wadleigh United States	38	4.7k 0.4×	5.3k 0.6×	3.5k 0.5×	1.8k 0.4×	1.0k 0.9×	134	7.7k
John Mascarenhas United States	40	3.7k 0.3×	3.2k 0.3×	2.7k 0.3×	1.5k 0.3×	915 0.8×	358	6.4k
Norbert Gattermann Germany	44	3.7k 0.3×	5.6k 0.6×	2.1k 0.3×	1.1k 0.2×	688 0.6×	256	7.2k
Mary Frances McMullin United Kingdom	43	4.4k 0.3×	4.2k 0.4×	3.6k 0.5×	1.5k 0.3×	664 0.6×	215	7.5k
Eva Hellström‐Lindberg Sweden	40	3.8k 0.3×	8.2k 0.9×	4.0k 0.5×	504 0.1×	1.2k 1.0×	187	10.6k
Tapan M. Kadia United States	57	3.9k 0.3×	9.8k 1.0×	5.4k 0.7×	803 0.2×	2.7k 2.3×	778	13.2k

Countries citing papers authored by Claire Harrison

Since Specialization

Citations

This map shows the geographic impact of Claire Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Harrison more than expected).

Fields of papers citing papers by Claire Harrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Harrison. The network helps show where Claire Harrison may publish in the future.

Co-authorship network of co-authors of Claire Harrison

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Harrison. A scholar is included among the top collaborators of Claire Harrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Harrison. Claire Harrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vachhani, Pankit, Ruben A. Mesa, John Mascarenhas, et al.. (2025). JAK inhibitor selection in challenging scenarios of myelofibrosis: a review. Haematologica.

Mascarenhas, John, et al.. (2024). The Use of Fedratinib (FEDR) for Myelofibrosis (MF) As a Potential Bridge to Hematopoietic Stem Cell Transplantation (HSCT) after Ruxolitinib (RUX) Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptoms, and Hematologic Response. Transplantation and Cellular Therapy. 30(2). S372–S372. 1 indexed citations

Harrison, Claire, Ruben A. Mesa, Moshe Talpaz, et al.. (2024). Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Haematology. 11(10). e729–e740. 11 indexed citations

Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2024). Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology. 114(2). 238–247. 3 indexed citations

Mascarenhas, John, Raajit K. Rampal, Prithviraj Bose, et al.. (2024). Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.. Journal of Clinical Oncology. 42(16_suppl). TPS6594–TPS6594. 1 indexed citations

McMullin, Mary Frances & Claire Harrison. (2024). How I treat patients with low-risk polycythemia vera who require cytoreduction. Blood. 145(16). 1717–1723. 3 indexed citations

Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842. 39 indexed citations

Verstovšek, Srđan, et al.. (2023). Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies. Cancer. 129(11). 1681–1690. 17 indexed citations

Gupta, Vikas, John Mascarenhas, Marina Kremyanskaya, et al.. (2023). Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Advances. 7(18). 5421–5432. 4 indexed citations

10.

Harrison, Claire, et al.. (2022). Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice. Current Research in Translational Medicine. 70(3). 103338–103338. 2 indexed citations

11.

Harrington, Patrick, Richard Dillon, Deepti Radia, et al.. (2022). Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype. British Journal of Haematology. 198(6). 1011–1015. 8 indexed citations

12.

Alimam, Samah, Richard Dillon, Michael A. Simpson, et al.. (2021). Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Advances. 5(4). 1059–1068. 14 indexed citations

13.

Harrington, Patrick, Hugues de Lavallade, Katie J. Doores, et al.. (2021). Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 35(12). 3573–3577. 31 indexed citations

14.

Mullally, Ann, John Hood, Claire Harrison, & Ruben A. Mesa. (2020). Fedratinib in myelofibrosis. Blood Advances. 4(8). 1792–1800. 60 indexed citations

15.

Curto‐García, Natalia, Andrew J. Doyle, Karen Breen, et al.. (2020). Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK. British Journal of Haematology. 189(3). e79–e81. 23 indexed citations

16.

Doyle, Andrew J., Karen Breen, Donal P. McLornan, et al.. (2019). Outcomes of Patients Receiving Direct Oral Anticoagulants for Myeloproliferative Neoplasm Associated Venous Thromboembolism. Blood. 134(Supplement_1). 4183–4183. 3 indexed citations

17.

Tefferi, Ayalew, Francesco Passamonti, Tiziano Barbui, et al.. (2013). Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. Blood. 122(21). 394–394. 24 indexed citations

18.

Scott, Linda M., et al.. (2007). JAK2 exon 12 mutations occur frequently in idiopathic erythrocytosis patients with low serum erythropoietin levels. Research Portal (Queen's University Belfast). 1 indexed citations

19.

Percy, Melanie J., Quan Zhao, Adrian Flores, et al.. (2006). A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proceedings of the National Academy of Sciences. 103(3). 654–659. 252 indexed citations

20.

Harrison, Claire, et al.. (1998). Evaluation of risk factors for thrombosis in patients with essential thrombocythaemia. UCL Discovery (University College London). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact